Indeed, myeloma and B cell lymphomas have been reported to resist TRAIL-induced killing (106), by downregulating TRAIL receptors—death receptor 4 (DR4) and DR5 (107, 108), or by dysregulating receptor signaling to evade killing (109, 110). This evidence concerns the gene TNFRSF10A and plasma cell myeloma.